assignment
Not Recruiting

Phase 2 Randomized Study of Adjuvant Apalutamide Versus Standard of Care in High-Risk Localized or Locally Advanced Prostate Adenocarcinoma Post-Radical Prostatectomy

Trial ID
2024-511832-29-00
Protocol
UKM17_0018

Register record, history and transparency: CTIS.eu

Trial statistics

science
1
test molecule
location_city
15
research sites
public
2
countries
medical_information
1
disease
person_search
15
investigators
handshake
2
vendors

Diseases & Conditions

Prostate cancer

Objectives

The primary objective of this study is to determine if adjuvant **apalutamide** in patients with high-risk, localized or locally advanced prostate cancer results in prolonged biochemically recurrence-free survival after radical prostatectomy (RPE) compared to the standard of care (SOC). This is clinically relevant as it addresses the potential for **apalutamide** to improve outcomes in patients at high risk of developing subsequent metastatic disease, thereby potentially reducing the incidence of biochemical recurrence and improving long-term survival rates.

Secondary objectives include:

  • Characterizing the safety and tolerability of **apalutamide** in subjects with high-risk, localized or locally advanced prostate cancer who have undergone RPE.
  • Determining if **apalutamide** results in an improvement of prostate-specific antigen doubling time (PSADT), specifically an increased PSADT in cases of biochemical recurrence (BCR).
These objectives are important for understanding the broader impact of **apalutamide** on patient safety and disease progression markers.

Participants

The clinical trial involves **male** participants exclusively, focusing on individuals aged 18 years and older. The study targets patients with **high-risk adenocarcinoma of the prostate** who have undergone radical prostatectomy. Participants are required to have a confirmed histological diagnosis and must meet specific criteria for high risk of disease recurrence, such as a Gleason score of 8 or higher, among other factors. The trial excludes individuals with metastatic disease, as confirmed by imaging techniques. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, indicating they are fully active or restricted in physically strenuous activity but ambulatory. The trial does not include a vulnerable population, and the sponsor has not provided the total number of participants. Lifestyle considerations such as diet and physical activity are not specified, but participants must have adequate hematologic, hepatic, and renal function to be eligible. The selection process ensures that participants have recovered from surgery and have a PSA level below 0.2 ng/ml prior to randomization.

Plans and Procedures

The clinical trial is designed to evaluate the efficacy of **apalutamide** as an adjuvant therapy in patients with high-risk adenocarcinoma of the prostate following radical prostatectomy. This is a randomized, open-label, Phase 2 study comparing the use of apalutamide to the standard of care. The primary objective is to determine if adjuvant apalutamide results in prolonged biochemically recurrence-free survival compared to standard treatment. The trial is expected to run from December 2020 to November 2027, with participant involvement lasting up to 840 days, depending on individual response and progression.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to confirm eligibility based on criteria such as age, ability to swallow tablets, and specific medical conditions. The inclusion criteria require participants to have histologically confirmed adenocarcinoma of the prostate, an ECOG performance status of 0 or 1, and no evidence of metastatic disease. Following the screening, eligible participants will be randomized to receive either apalutamide or standard care. The study medication is administered orally in the form of film-coated tablets, with a maximum daily dose of 240 mg.

Throughout the trial, participants will attend regular follow-up visits to monitor their health status, treatment adherence, and any adverse events. These visits are crucial for assessing the primary endpoint of progression-free survival, defined as the time from randomization until biochemical recurrence, metastases, or death from any cause. The end-of-study visit will conclude the participant's involvement, unless early termination is warranted due to disease progression, unacceptable toxicity, or withdrawal of consent. The trial's design ensures rigorous monitoring and data collection to evaluate the potential benefits of apalutamide in this patient population.

Treatment

The clinical trial involves the administration of the experimental medication **JNJ-56021927**, which contains the active substance **apalutamide**. This medication is provided in the form of a **film-coated tablet** and is intended for **oral use**. The maximum daily dose of apalutamide is 240 mg, with a total maximum dose of 201,600 mg over the course of the treatment period, which spans up to 840 days. The medication is of chemical origin and is not formulated for pediatric use. The trial aims to evaluate the efficacy of adjuvant apalutamide in patients with high-risk, localized or locally advanced prostate cancer following radical prostatectomy.

In addition to the experimental treatment, the study includes a comparator treatment, which is the **standard-of-care therapy** for prostate cancer. This standard treatment serves as a control to assess the effectiveness of apalutamide in prolonging biochemically recurrence-free survival in the target patient population. The standard-of-care therapy is administered according to established clinical guidelines and practices for managing high-risk prostate cancer post-surgery.

Participant compliance with the dosing regimen is monitored throughout the study to ensure adherence to the prescribed treatment schedule. This monitoring is crucial for accurately assessing the therapeutic outcomes and safety profile of the experimental medication in comparison to the standard-of-care therapy. The trial is conducted under the sponsorship of Janssen-Cilag International N.V., with a focus on determining the potential benefits of apalutamide in reducing the risk of metastatic disease development in the specified patient cohort.

Efficacy

Efficacy in this clinical trial will be assessed primarily through the endpoint of **Progression-free survival (PFS)**. This endpoint is defined as the time interval from randomization until biochemical recurrence (BCR), metastases, or death from any cause, whichever occurs first. The trial aims to determine if adjuvant apalutamide in patients with high-risk, localized or locally advanced prostate cancer results in prolonged biochemically recurrence-free survival after radical prostatectomy compared to the standard of care. The measurement and analysis of PFS will be conducted at specified intervals throughout the trial duration, ensuring a comprehensive evaluation of the treatment's efficacy. The trial is designed as a randomized, open-label, Phase 2 study, focusing on the safety and efficacy of apalutamide as a potential therapy for prostate cancer patients at high risk of developing subsequent metastatic disease.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Signed informed consent form (ICF)
  • Men ≥ 18 years of age
  • Patients with histologically confirmed adenocarcinoma of the prostate after radical prostatectomy
  • Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
  • Exclusion of metastatic disease by CT-scan of abdomen (MRI of abdomen is possible) and bone scan prior to study inclusion. A PSMA PET-CT/MRI is possible. In this case it has to be done with a diagnostic CT/MRI with contrast media and not with a low dose CT-scan only. In case PSMA-PET imaging has been done, a bone scan can be omitted. CT/MRI, and bone-scan imaging or PSMA PET-CT/MRI administered ≤12 weeks before RPE may be used for screening
  • Patients after RPE must meet the d'Amico criteria for high risk of disease recurrence (T-stage and Gleason-score determined after radical prostatectomy) i.e. 1 of the following after RPE: 1) Gleason score ≥8, any T-stage, any iPSA or 2) Gleason score 6 or 7, any iPSA and ≥pT3 or 3) iPSA >20 ng/ml, any Gleason score, any T-stage.
  • Patients have to have recovered from radical prostatectomy within eight weeks to be able to take part in the study
  • PSA must have declined below 0.2 ng/ml prior to randomization
  • Adequate hematologic, hepatic, and renal function: • Hematologic i) Haemoglobin ≥ 9.0 g/dL independent of transfusions ii) Neutrophils ≥ 1.5 Ths./μL • Hepatic i) Total Bilirubin =< 1.5X upper limit of normal (ULN) [except for subjects with documented Gilbert's disease in which case total bilirubin not to exceed 10X ULN] ii) Alanine (ALT) and aspartate (AST) aminotransferase =< 2.5X ULN • Renal: i) Serum creatinine <1.5X ULN or calculated creatinine clearance ≥ 50 mL/min ii) Serum potassium ≥ 3.5 mM iii) Serum albumin ≥ 3.0 g/dL
  • Ability to swallow study medication tablets
  • In case of apalutamide treatment: Agrees to use a condom and another highly effective method of birth control if he is having sex with a woman of childbearing potential or to use a condom if he is having sex with a woman who is pregnant
cancel

Exclusion Criteria

  • Any chronic medical condition requiring a higher dose of corticosteroid than 10mg prednisone/prednisolone q.d.
  • Prior cytotoxic chemotherapy or biologic therapy for the treatment of prostate cancer
  • Prior or current treatment of prostate cancer with apalutamide, enzalutamide, darolutamide, or other investigational agents targeting the androgen receptor
  • Prior therapy with Sipuleucel-T or other vaccination or immunogenic therapy for the treatment of prostate cancer
  • Prior treatment with abiraterone acetate or other androgen synthesis inhibitors (e. g. ketoconazole, TAK700, TOK001)
  • Use of 5-α reductase inhibitors (eg, dutasteride, finasteride) ≤4 weeks prior to randomization
  • Prior surgical castration or medical castration using LHRH-Agonists or GnRH-Antagonists
  • Prior or current radiation or radionuclide (including radium-223 dichloride) therapy for treatment of prostate cancer (adjuvant radiation of the prostate bed without involvement of the regional lymph node template as by standard of care in case of positive surgical margins (R1) is allowed)
  • Prior or current systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4 weeks of Cycle 1, Day 1
  • Any lymph node or distant metastasis
  • History of seizures or condition that may predispose to seizure (including, but not limited to prior stroke, transient ischemic attack or loss of consciousness ≤1 year prior to randomization; brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect).
  • Current or prior treatment with anti-epileptic medications for the treatment of seizures
  • Management of cardiovascular risk factors, such as hypertension, diabetes or dyslipidaemia should be optimised as per standard of care before treatment with apalutamide will be initiated 13.1. Uncontrolled hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg. For patients with relevant comorbidities (e.g. diabetes) systolic BP ≥130 mmHg or diastolic BP ≥80 mmHg). Patients with a history of hypertension are allowed provided that blood pressure is controlled by anti-hypertensive treatment 13.2. Patients with uncontrolled diabetes defined as HbA1c ≥7.5% 13.3. Patients with a dyslipidemia defined as LDL cholesterol >100 mg/dl. For patients with a dyslipidemia defined as LDL cholesterol >100 mg/dl and SCORE-value of 1-5%: In case of a SCORE-value of <1% a LDL cholesterol level of up to 115 mg/dl is acceptable. In case of increased LDL cholesterol above these values a statin-therapy can be initiated and a rescreening within 4 weeks is possible 13.4. Cardiovascular risk assessment via an appropriate score (e.g. the SCORE-Chart for the European high/low risk score from the European Society of Cardiology) and ≥ borderline risk i.e. 10% of developing cardiovascular events within 10 years without prior cardiovascular disease
  • Active or symptomatic viral hepatitis or chronic liver disease or HIV
  • History of pituitary or adrenal dysfunction
  • Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 12 months, severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart disease or cardiac ejection fraction measurement of <50% at baseline, or clinically relevant pelvic lymphocele after radical prostatectomy as evaluated by clinical examination and/or pelvic ultrasound (if a risk is present, patients may be allowed to be enrolled after adaptive risk management).
  • Any condition that requires treatment with digoxin, digitoxin, and other digitalis drugs
  • Long QT Syndrome
  • Atrial Fibrillation, or other cardiac arrhythmia requiring therapy
  • Other malignancy with a ≥30% probability of recurrence within 24 months, except non-melanoma skin cancer
  • Any condition, which, in the opinion of the investigator, would preclude participation in this trial.
  • Gastrointestinal conditions affecting absorption
  • Hypersensitivity to the active substance, or to any of the excipients of the study medication
  • Any psychological, cognitive, familial, sociological or geographical condition that, in the investigator's opinion, compromises the patient's ability to understand the patient information, to give informed consent or to comply with the study protocol.
  • Participation in another interventional clinical trial during this trial or within 4 weeks before entry into this trial. There may be exceptions at the discretion of the (coordinating) investigator.

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Austria AustriaNot Recruiting01 Dec 202060
Germany GermanyNot Recruiting01 Dec 2020130

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
JNJ-56021927
TestFILM-COATED TABLETORAL USE240840PRD4402768

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Apalutamide
27 trials

Also investigated for

Prostate cancer 13Hormone-dependent prostate cancer 6Prostate cancer metastatic 6Hormone-refractory prostate cancer 3